3 Healthcare Stock Stories for Thursday Perusal

Gilead Sciences (NASDAQ:GILD): Closing price $52.18

On Wednesday, Gilead announced plans to begin a third Phase 3 clinical trial of its investigational fixed-dose combination tablet of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C virus infection. The evaluation, ION-3, will examine the once-daily fixed-dose combination of sofosbuvir and ledipasvir for eight weeks, with and without ribavirin, and for 12 weeks without RBV in 600 non-cirrhotic, treatment-naïve genotype 1 HCV-infected patients. The design of ION-3 was created on interim results from the Phase 2 LONESTAR study, which evaluated eight- and 12-week courses of therapy with the once-daily fixed-dose combination of sofosbuvir and ledipasvir, with and without RBV, in 60 treatment-naïve, non-cirrhotic patients.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

GILD

Hyperion Therapeutic (NASDAQ:HPTX): Closing price $20.53

The firm reported Wednesday that it was advised by the FDA that Ravicti (glycerol phenylbutyrate) Liquid has qualified for orphan drug exclusivity for seven years from the date of the approval on February 1st.  Ravicti is indicated for use as a nitrogen-binding agent for chronic management of adult and pediatric patients two years of age suffering with UCD that can not be managed by dietary protein restriction and/or amino acid supplementation alone. The drug must be used alongside dietary protein restriction and in some situations, dietary supplements (i.e. essential amino acids, arginine, citrulline, protein-free calorie supplements).

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

HPTX

AVEO Oncology (NASDAQ: AVEO): Closing price $2.65

AVEO and Astellas Pharma reported Wednesday that the FDA’s  Oncologic Drugs Advisory Committee voted 13 to 1 that the application for investigational agent tivozanib did not show a favorable benefit-to-risk evaluation for the treatment of advanced renal cell carcinoma in an adequate and well-controlled trial.  Shares were halted on the news but later resumed trading.

 

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

AVEO

Investing Insights: Does Celgene Still Have Upside Potential?